Cruising Review

MODS Treatment with PEMF

Bemer Review
Comprehensive review of Bemer and PEMF (Pulsed Electromagnetic Field). Explore scientific research, studies, and articles on the benefits and applications of Bemer and PEMF therapy for health and wellness.

Publication Title | MODS Treatment with PEMF

Health Web PEMF Search Series

Cruising Review Publications search was updated real-time via Filemaker on:

Cruising Review Publications | Return to Search List

Search Completed | Title | MODS Treatment with PEMF
Original File Name Searched: 392_2023_Article_2293.pdf | Google It | Yahoo | Bing

Previous Page | Next Page
mods-treatment-with-pemf-001</TD> <TD valign=

Page | 001

Clinical Research in Cardiology (2024) 113:260–275
Treatment of patients with multiple organ dysfunction syndrome (MODS) with an electromagnetic field coupled to biorhythmically defined impulse configuration: the MicrocircMODS study
Karl Werdan1 · Sebastian Nuding1,2 · Diethelm Kühnert1,3 · Ramzi Kolthoum1 · Artjom Schott1 · Felix Quitter4 · Andreas Wienke5 · Daniel Sedding1
Received: 30 April 2023 / Accepted: 21 August 2023 / Published online: 17 September 2023 © The Author(s) 2023
Background To potentially improve impaired vasomotion of patients with multiple organ dysfunction syndrome (MODS), we tested whether an electromagnetic field of low flux density coupled with a biorhythmically defined impulse configuration (Physical Vascular Therapy BEMER®, PVT), in addition to standard care, is safe and feasible and might improve disturbed microcirculatory blood flow and thereby improve global haemodynamics.
Methods In a prospective, monocentric, one-arm pilot study, 10 MODS patients (APACHE II score 20–35) were included. Patients were treated, in addition to standard care, for 4 days with PVT (3 treatment periods of 8 min each day; day 1: field intensity 10.5 μT; day 2:14 μT, day 3:17.5 μT; day 4:21.0 μT). Primary endpoint was the effect of PVT on sublingual micro- circulatory perfusion, documented by microvascular flow index (MFI). Patient safety, adverse events, and outcomes were documented.
Results An increase in MFI by approximately 25% paralleled 4-day PVT, with the increase starting immediately after the first PVT and lasting over the total 4-day treatment period. Concerning global haemodynamics (secondary endpoints), halv- ing vasopressor use within 24 h, and haemodynamic stabilisation paralleled 4-day PVT with an increase in cardiac index, stroke volume index, and cardiac power index by 30%–50%. No adverse events (AEs) or serious adverse events (SAEs) were classified as causally related to the medical product (PVT) or study. Three patients died within 28 days and one patient between 28 and 180 days.
Conclusion PVT treatment was feasible and safe and could be performed without obstruction of standard patient care. An increase in microcirculatory blood flow, a rapid reduction in vasopressor use, and an improvement in global haemodynamics paralleled PVT treatment. Findings of this pilot study allowed forming a concept for a randomized trial for further proof.
Karl Werdan and Sebastian Nuding should be considered as the shared first authors.
* Karl Werdan
3 4 5
04838 Zschepplin, Germany 01277 Dresden, Germany
Institute of Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Magdeburger Strasse 8, 06112 Halle (Saale), Germany
Department of Internal Medicine III, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, 06097 Halle (Saale), Germany
Hospital St. Elisabeth and St. Barbara, 06110 Halle (Saale),

Search Contact: